Protalix Biotherapeutics Net Income
| PLX Stock | USD 2.34 0.27 13.04% |
As of the 31st of January, Protalix Biotherapeutics holds the Coefficient Of Variation of (2,640), variance of 10.41, and Risk Adjusted Performance of (0.02). Compared to fundamental indicators, the technical analysis model allows you to check existing technical drivers of Protalix Biotherapeutics, as well as the relationship between them.
Protalix Biotherapeutics Total Revenue |
|
Gross Profit | Profit Margin | Market Capitalization | Enterprise Value Revenue 2.3493 | Revenue |
| Last Reported | Projected for Next Year | ||
| Net Income | 2.6 M | 2.8 M | |
| Net Income From Continuing Ops | 3.4 M | 3.5 M | |
| Net Income Applicable To Common Shares | 3.4 M | 3.5 M | |
| Net Income Per Share | 0.04 | 0.04 | |
| Net Income Per E B T | 0.81 | 0.85 |
Protalix | Net Income | Build AI portfolio with Protalix Stock |
The evolution of Net Income for Protalix Biotherapeutics provides essential context for understanding the company's financial health trajectory. By analyzing this metric's behavior over time, investors can assess whether recent trends align with long-term patterns, and how Protalix Biotherapeutics compares to historical norms and industry peers.
Latest Protalix Biotherapeutics' Net Income Growth Pattern
Below is the plot of the Net Income of Protalix Biotherapeutics over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in Protalix Biotherapeutics financial statement analysis. It represents the amount of money remaining after all of Protalix Biotherapeutics operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is Protalix Biotherapeutics' Net Income historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Protalix Biotherapeutics' overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported 2.93 M | 10 Years Trend |
|
Net Income |
| Timeline |
Protalix Net Income Regression Statistics
| Arithmetic Mean | (13,978,105) | |
| Coefficient Of Variation | (205.19) | |
| Mean Deviation | 19,824,242 | |
| Median | (14,927,000) | |
| Standard Deviation | 28,681,350 | |
| Sample Variance | 822.6T | |
| Range | 141.5M | |
| R-Value | 0.21 | |
| Mean Square Error | 840.3T | |
| R-Squared | 0.04 | |
| Significance | 0.43 | |
| Slope | 1,169,490 | |
| Total Sum of Squares | 13161.9T |
Protalix Net Income History
Other Fundumenentals of Protalix Biotherapeutics
| Net Income From Continuing Ops | ||
| Net Income Applicable To Common Shares | ||
| Net Income Per Share | ||
| Net Income Per E B T |
Protalix Biotherapeutics Net Income component correlations
Protalix Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Protalix Biotherapeutics is extremely important. It helps to project a fair market value of Protalix Stock properly, considering its historical fundamentals such as Net Income. Since Protalix Biotherapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Protalix Biotherapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Protalix Biotherapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Protalix Biotherapeutics. Anticipated expansion of Protalix directly elevates investor willingness to pay premium valuations. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Protalix Biotherapeutics assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Quarterly Earnings Growth (0.01) | Earnings Share 0.08 | Revenue Per Share | Quarterly Revenue Growth (0.01) | Return On Assets |
The market value of Protalix Biotherapeutics is measured differently than its book value, which is the value of Protalix that is recorded on the company's balance sheet. Investors also form their own opinion of Protalix Biotherapeutics' value that differs from its market value or its book value, called intrinsic value, which is Protalix Biotherapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Protalix Biotherapeutics' market value can be influenced by many factors that don't directly affect Protalix Biotherapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
It's important to distinguish between Protalix Biotherapeutics' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Protalix Biotherapeutics should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Meanwhile, Protalix Biotherapeutics' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.
Protalix Biotherapeutics 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Protalix Biotherapeutics' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Protalix Biotherapeutics.
| 11/02/2025 |
| 01/31/2026 |
If you would invest 0.00 in Protalix Biotherapeutics on November 2, 2025 and sell it all today you would earn a total of 0.00 from holding Protalix Biotherapeutics or generate 0.0% return on investment in Protalix Biotherapeutics over 90 days. Protalix Biotherapeutics is related to or competes with Sellas Life, Coherus BioSciences, Invivyd, Protara Therapeutics, Codexis, OmniAb, and NeOnc Technologies. Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombi... More
Protalix Biotherapeutics Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Protalix Biotherapeutics' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Protalix Biotherapeutics upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.06) | |||
| Maximum Drawdown | 16.17 | |||
| Value At Risk | (4.64) | |||
| Potential Upside | 3.5 |
Protalix Biotherapeutics Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Protalix Biotherapeutics' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Protalix Biotherapeutics' standard deviation. In reality, there are many statistical measures that can use Protalix Biotherapeutics historical prices to predict the future Protalix Biotherapeutics' volatility.| Risk Adjusted Performance | (0.02) | |||
| Jensen Alpha | (0.16) | |||
| Total Risk Alpha | (0.36) | |||
| Treynor Ratio | (0.23) |
Protalix Biotherapeutics January 31, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | (0.02) | |||
| Market Risk Adjusted Performance | (0.22) | |||
| Mean Deviation | 2.43 | |||
| Coefficient Of Variation | (2,640) | |||
| Standard Deviation | 3.23 | |||
| Variance | 10.41 | |||
| Information Ratio | (0.06) | |||
| Jensen Alpha | (0.16) | |||
| Total Risk Alpha | (0.36) | |||
| Treynor Ratio | (0.23) | |||
| Maximum Drawdown | 16.17 | |||
| Value At Risk | (4.64) | |||
| Potential Upside | 3.5 | |||
| Skewness | 0.2862 | |||
| Kurtosis | 3.09 |
Protalix Biotherapeutics Backtested Returns
At this stage we consider Protalix Stock to be very risky. Protalix Biotherapeutics maintains Sharpe Ratio (i.e., Efficiency) of close to zero, which implies the firm had a close to zero % return per unit of risk over the last 3 months. We have found twenty-three technical indicators for Protalix Biotherapeutics, which you can use to evaluate the volatility of the company. Please check Protalix Biotherapeutics' Coefficient Of Variation of (2,640), variance of 10.41, and Risk Adjusted Performance of (0.02) to confirm if the risk estimate we provide is consistent with the expected return of 0.0278%. The company holds a Beta of 0.56, which implies possible diversification benefits within a given portfolio. As returns on the market increase, Protalix Biotherapeutics' returns are expected to increase less than the market. However, during the bear market, the loss of holding Protalix Biotherapeutics is expected to be smaller as well. Protalix Biotherapeutics right now holds a risk of 3.6%. Please check Protalix Biotherapeutics treynor ratio, accumulation distribution, as well as the relationship between the Accumulation Distribution and period momentum indicator , to decide if Protalix Biotherapeutics will be following its historical price patterns.
Auto-correlation | -0.69 |
Very good reverse predictability
Protalix Biotherapeutics has very good reverse predictability. Overlapping area represents the amount of predictability between Protalix Biotherapeutics time series from 2nd of November 2025 to 17th of December 2025 and 17th of December 2025 to 31st of January 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Protalix Biotherapeutics price movement. The serial correlation of -0.69 indicates that around 69.0% of current Protalix Biotherapeutics price fluctuation can be explain by its past prices.
| Correlation Coefficient | -0.69 | |
| Spearman Rank Test | -0.54 | |
| Residual Average | 0.0 | |
| Price Variance | 0.03 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Protalix Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, Protalix Biotherapeutics reported net income of 2.93 M. This is 99.14% lower than that of the Biotechnology sector and 95.81% lower than that of the Health Care industry. The net income for all United States stocks is 99.49% higher than that of the company.
Protalix Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Protalix Biotherapeutics' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Protalix Biotherapeutics could also be used in its relative valuation, which is a method of valuing Protalix Biotherapeutics by comparing valuation metrics of similar companies.Protalix Biotherapeutics is currently under evaluation in net income category among its peers.
Protalix Biotherapeutics ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Protalix Biotherapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Protalix Biotherapeutics' managers, analysts, and investors.Environmental | Governance | Social |
Protalix Fundamentals
| Return On Equity | 0.13 | ||||
| Return On Asset | 0.0553 | ||||
| Profit Margin | 0.09 % | ||||
| Operating Margin | 0.12 % | ||||
| Current Valuation | 145.28 M | ||||
| Shares Outstanding | 80.42 M | ||||
| Shares Owned By Insiders | 10.15 % | ||||
| Shares Owned By Institutions | 17.88 % | ||||
| Number Of Shares Shorted | 4.55 M | ||||
| Price To Earning | (1.23) X | ||||
| Price To Book | 3.15 X | ||||
| Price To Sales | 2.69 X | ||||
| Revenue | 53.4 M | ||||
| Gross Profit | 35.58 M | ||||
| EBITDA | 6.52 M | ||||
| Net Income | 2.93 M | ||||
| Cash And Equivalents | 19.76 M | ||||
| Cash Per Share | 0.41 X | ||||
| Total Debt | 5.53 M | ||||
| Current Ratio | 1.33 X | ||||
| Book Value Per Share | 0.66 X | ||||
| Cash Flow From Operations | 8.67 M | ||||
| Short Ratio | 5.66 X | ||||
| Earnings Per Share | 0.08 X | ||||
| Price To Earnings To Growth | (0.10) X | ||||
| Target Price | 11.0 | ||||
| Number Of Employees | 213 | ||||
| Beta | -0.25 | ||||
| Market Capitalization | 166.47 M | ||||
| Total Asset | 73.42 M | ||||
| Retained Earnings | (378.39 M) | ||||
| Working Capital | 34.46 M | ||||
| Current Asset | 59.65 M | ||||
| Current Liabilities | 10.33 M | ||||
| Net Asset | 73.42 M |
About Protalix Biotherapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Protalix Biotherapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Protalix Biotherapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Protalix Biotherapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Protalix Stock Analysis
When running Protalix Biotherapeutics' price analysis, check to measure Protalix Biotherapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Protalix Biotherapeutics is operating at the current time. Most of Protalix Biotherapeutics' value examination focuses on studying past and present price action to predict the probability of Protalix Biotherapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Protalix Biotherapeutics' price. Additionally, you may evaluate how the addition of Protalix Biotherapeutics to your portfolios can decrease your overall portfolio volatility.